Web Analytics

3 Latest Announced Rounds

  • $5,500,000
    Unknown

    6 Investors

    Financial Services
    May 1st, 2025
  • $3,750,000
    Pre Series A

    3 Investors

    E-learning Providers
    May 1st, 2025
  • $7,300,000
    Seed

    3 Investors

    Financial Services
    May 1st, 2025
$1,436.14M Raised in 58 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Curevo Vaccine

start up
United States - Bothell, Washington
  • 19/03/2025
  • Series B
  • $110,000,000

Curevo Vaccine is a clinical-stage developer of vaccines for varicella and herpes zoster. Amezosvatein (CRV-101) is an adjuvanted subunit (non-mRNA) vaccine designed to prevent herpes zoster, commonly known as shingles. Our goal with a new herpes zoster vaccine is to improve the patient experience and, ultimately, overall vaccination rates, by developing amezosvatein as a vaccine with non-inferior efficacy combined with clinically-meaningful improvements in reactogenicity when compared to Shingrix.


Related People

George SimeonFounder

George Simeon United States - Greater Seattle Area

Strategic Alliances, Global Commercialisation, M&A, Joint-Ventures, Organization Building
Balance between: Strategic Thinking - Creative Problem Solving - 'Hands-on' Execution